Efficacy News and Research

RSS

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.

9 May 2011

Diamyd Medical announces European Phase III study results in type 1 diabetes

Diamyd Medical reports that results from its European Phase III study with the antigen-based therapy Diamyd did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed type 1 diabetes patients.

9 May 2011

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, announces that the U.S. Food and Drug Administration has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy.

9 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

Study confirms prognostic role of CTC in metastatic breast cancer

French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.

7 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Research roundup: Racial disparities in cancer screening and VA treatment

Racial And Ethnic Disparities In Colorectal Cancer Screening Persisted Despite Expansion Of Medicare's Screening Reimbursement. This study looked at the effect in minority groups of expanded reimbursements by Medicare for colorectal cancer screenings.

7 May 2011

Tufts Health Plan now covers SBi's STAR total ankle replacement system

Small Bone Innovations, Inc. (SBi) announced today that effective July 1, 2011, Tufts Health Plan, covering approximately 742,000 members in Massachusetts and Rhode Island, is revising its reimbursement policy to cover SBi's STAR™ total ankle replacement system. The decision means that 98 percent of all privately-insured lives in Massachusetts will have access to total ankle replacement.

7 May 2011

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported results from three studies in relapsed multiple myeloma. Two of the studies examined the use of VELCADE for Injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.

6 May 2011

Man with no pulse for 96 minutes makes complete recovery

By all counts, the 54-year-old man who collapsed on a recent winter night in rural Minnesota would likely have died. He'd suffered a heart attack, and even though he was given continuous CPR and a series of shocks with a defibrillator, the man was without a pulse for 96 minutes.

6 May 2011

Pacira to present EXPAREL data in postsurgical pain at two medical meetings

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that clinical and preclinical data highlighting the safety and efficacy of EXPAREL™ will be presented at two medical meetings.

6 May 2011

Omeros' PDE7 program expands addiction franchise

Omeros Corporation today announced that its phosphodiesterase 7 inhibitors demonstrated robust efficacy in animal models of nicotine addiction.

6 May 2011

Cook Medical introduces new Formula renal stent at SCAI 2011

Patients suffering from blockages of the arteries to the kidneys now have access to a new stenting treatment option with the launch today of Cook Medical's Formula Renal Balloon-Expandable Stent at the Society for Cardiovascular Angioplasty and Intervention 2011 Scientific Sessions.

6 May 2011

COIN hosts nanobiotechnology event on nanomedicines and the regulatory path

The Center of Innovation for Nanobiotechnology (COIN) today announced the upcoming NanoBio Executive Roundtable event to be hosted at RTP Foundation in Durham, NC on May 17, 2011. This Roundtable will tackle regulatory issues surrounding nanomedicine commercialization. The “Nanomedicines and the Regulatory Path” Roundtable will kick off with a presentation from Katherine Tyner, Ph.D., a Chemist in the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA).

5 May 2011

CytRx reports $6.3 million net loss for first quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2011, and provided a business update.

5 May 2011

Pfizer’s Revatio receives European Commission approval for pediatric treatment of pulmonary arterial hypertension

Pfizer Inc. announced that Revatio (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.

5 May 2011

Over 1000 patients enrolled in world's largest ever pancreatic cancer vaccine trial

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that it had been officially notified by the independent Data Monitoring Committee that over 1000 patients have been enrolled in the TeloVac Study, making it the world's largest ever pancreatic cancer vaccine trial.

5 May 2011

S*BIO regains North American, European rights to novel JAK2 inhibitors from Onyx

S*BIO Pte Ltd today announced the restructuring of its collaboration and option agreement with Onyx Pharmaceuticals, which was entered into in January 2009.

5 May 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation, the most common form of cardiac arrhythmia.

5 May 2011